Regulating Blood Sugar: Balanced blood sugar levels help prevent insulin spikes, which can lead to fat storage, especially around the midsection
Even moderate doses (8 mg) led to ~2223% weight loss, highlighting a dose-responsive effect
Side Effects and Medical Monitoring Common Side Effects to Expect When starting GLP-1 agonists, gastrointestinal issues are the most frequent side effects, especially in the early weeks or when increasing the dosage
#Nephrology #Dialysis #Semaglutide #GLP1 #Diabetes #Cardiovascular #EASD2025 #PatientSafety #MedicalResearch To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)